Clinical Research Directory

Inclusion Criteria: * ≥ 18 years and ≤ 65 years of age * Admitted to burn center within 72 hours of thermal burn injury * Estimated Total Body Surface area (TBSA) ≤ 30% * Surgical team has plans for surgical management of the burn wound (e.g. xenograft and/or autograft). * Patients experience a thermal burn injury, not an electrical or chemical burn. * Has a telephone to receive follow-up calls. * Able to speak and read English * Resides within 150 miles of study site * Alert and oriented * Willing to take study medication for 6 weeks following enrollment * Subjects are capable of giving informed consent. * Predicted probability of chronic pain ≥ 0.3 when demographic parameters are entered into a logistic regression model developed from a previous cohort. (Initial pain score entered into this model will be based on the highest pain severity over the initial 24 hours of hospital admission). * European American or African American Exclusion Criteria: * Unwilling to take study drug * Allergy to fish oil or corn/soybean oil. * Patient taking clopidogrel (Plavix) * Patient taking warfarin or dabigatran. * Substantial comorbid injury (e.g. long bone fracture) * Pregnancy/Breastfeeding * Prisoner status * Chronic daily opioid use prior to burn (\>20 mg oral daily morphine equivalents). * Active psychosis, suicidal ideation, or homicidal ideation * Requires an escharotomy or fasciotomy for the treatment of burn injury. * Has a disorder of pain processing or diminished capacity to perceive pain (congenital insensitivity to pain) * Known Child-Pugh liver disease severity classification B or C. * Known chronic kidney disease stage 4 or higher (GFR≤29). * Known Hemophilia A/B * Known bleeding dyscrasia * History of an inability to tolerate fish oil or corn/soybean oil. * Severe gastroesophageal reflux disease * No other history or condition that would, in the investigator's judgment, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g. might interfere with the study, confound interpretation, or endanger patient). * Intubated and sedated at time of enrollment. * Hypersensitivity to Vitamin D3, ergocalciferol, calcitriol, alfacalcidol, calcipotriol * Hypercalcemia (if not already completed, this will be assessed by clinical labs with albumin correction prior to enrollment). * Hypervitaminosis * Sarcoidosis * Hyperphosphatemia * Arteriosclerosis * Active myocardial ischemia * Frequent antacid use (calcium carbonate, cimetidine) * Cholestyramine or Colestipol use * Taking Vitamin D supplements in excess of 800 IU daily. * Taking \>1g of fish oil per day.